-
Epigenic Therapeutics Announced to be listed in“Forbes Asia 100 To Watch 2024”
Shanghai, China, 29 August 2024—Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, officially announced to be listed in “Forbes Asia 100 To Watch 2024”.
2024/09/02 -
Epigenic Therapeutics to present preclinical update of company's epigenome modulation technology for elimination of HBV viral antigens at 2024 annual conference of the European Association for the Study of the Liver
Shanghai, China, 10 May 2024- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, announced acceptance of an oral presentation at the European Association for the Study of the Liver (EASL) to be held in Milan, Italy, 5-8 J
2024/05/01
-
022024/092024/09/02Epigenic Therapeutics Announced to be listed in“Forbes Asia 100 To Watch 2024”
Shanghai, China, 29 August 2024—Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, officially announced to be listed in “Forbes Asia 100 To Watch 2024”.
-
012024/052024/05/01Epigenic Therapeutics to present preclinical update of company's epigenome modulation technology for elimination of HBV viral antigens at 2024 annual conference of the European Association for the Study of the Liver
Shanghai, China, 10 May 2024- Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, announced acceptance of an oral presentation at the European Association for the Study of the Liver (EASL) to be held in Milan, Italy, 5-8 J
-
282023/102023/10/28Epigenic Therapeutics to Present Company's Epigenetic Modulation Technology in Enhancement of CAR-T Function at SITC 2023
Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced to present a poster at The Society for Immunotherapy of Cancer(SITC)38th Annual Meeting on November 1-5 at California.
-
202023/102023/10/20Epigenic Therapeutics to Present Company's Leading Drug Discovery Program Using Epigenetic Modulation Technology at ESGCT 2023
Epigenic Therapeutics, a leading biotechnology company dedicated to developing next-generation gene modulation therapy utilizing epigenome regulation to treat prevalent diseases, today announced to present a poster at European Society of Gene & Cell Therapy(ESGCT)Conference on October 24-27 at Brussels, Belgium.
-
282023/092023/09/28Epigenic Therapeutics to Participate in the Chardan 7th Annual Genetic Medicines Conference
Epigenic Therapeutics is a frontier biotechnology company dedicated to developing next generation gene editing therapy utilizing regulation of epigenetic genome for a variety of diseases.
- 1
- 2